Antidepressants and Hair Loss: Which Ones, Why, and What to Do
Antidepressants are among the most commonly reported medications in dermatology consults for new-onset diffuse hair shedding. The signal is real, but it is also frequently misunderstood. The shedding pattern is almost always telogen effluvium (a temporary, diffuse shed), not the kind of patterned thinning seen in androgenetic alopecia. It tends to be self-limited, often improves while the medication is continued, and is rarely a reason to stop treatment on your own.
What follows is a practical breakdown of which classes have the strongest signal, when shedding typically starts, what to expect over time, and how to think about the conversation with a prescriber when the hair loss is bothersome.
Why antidepressants can cause shedding
The leading mechanism is telogen effluvium: a stressor pushes a higher-than-normal fraction of follicles from the growth (anagen) phase prematurely into the resting (telogen) phase. About two to three months later, those resting follicles release their hairs in a synchronized shed. The body interprets a range of inputs as stressors, including illness, surgery, large weight changes, nutritional shifts, hormonal changes, and certain medications.
Antidepressants likely contribute through several overlapping pathways: direct effects on neurotransmitter systems that influence the hair cycle, secondary effects on thyroid function (some agents can shift TSH), metabolic and weight changes that themselves trigger telogen effluvium, and individual sensitivity that is genetically variable. The depression itself, untreated, can also cause hair shedding through sleep disruption, appetite changes, and stress physiology, so untangling the medication from the underlying condition is not always straightforward.
The biological signature matches: diffuse shedding over the whole scalp, more hair than usual in the shower drain and on the pillow, a feeling of thinning ponytail or thinner overall density, but no bald patches and no clear concentration in the crown or temples.
Which antidepressants have the strongest signal
The literature on this is uneven. Most data comes from case reports, post-marketing surveillance, and a few retrospective cohort analyses. The picture that emerges:
Bupropion (Wellbutrin) has the strongest signal among commonly prescribed antidepressants. A widely cited retrospective cohort study using electronic health records (Etminan et al., SkinMed, 2018) found bupropion users had a notably higher rate of hair-loss diagnoses than users of several SSRIs in the same dataset. The absolute risk is still low, but bupropion stands out compared with peers.
SSRIs (selective serotonin reuptake inhibitors) all carry some reports, with the most frequently named being sertraline (Zoloft), paroxetine (Paxil), fluoxetine (Prozac), escitalopram (Lexapro), and citalopram (Celexa). Within the class the signal is fairly similar, with paroxetine and sertraline appearing slightly more often in published case series.
SNRIs (serotonin-norepinephrine reuptake inhibitors) including venlafaxine (Effexor) and duloxetine (Cymbalta) also have case reports. Venlafaxine is reported more often than duloxetine in the dermatology literature, but the data are thin.
Tricyclic antidepressants such as amitriptyline and nortriptyline have older reports of hair shedding. They are prescribed less often now for depression but are still common for chronic pain and migraine prevention, so the association comes up in those contexts.
Mirtazapine (Remeron) and trazodone have fewer reports relative to how often they are prescribed.
MAOIs are rarely prescribed today and the data are sparse.
Two cautions on interpreting any list like this. First, an antidepressant that is prescribed more often will accumulate more reports simply through volume; rate comparisons are more meaningful than raw counts. Second, the underlying condition (depression, anxiety, post-traumatic stress) is itself a hair-shedding risk factor, which inflates the apparent rate for whichever drug is most commonly used in the population being studied.
Timing: when shedding typically starts and stops
The classic telogen-effluvium time course applies. Shedding usually begins about 6 to 12 weeks after starting the medication or after a meaningful dose increase. It peaks over the following one to three months and then improves on its own. Most patients see the shedding stabilize within 6 months and recover most of their density within 6 to 12 months even if they continue the medication, because the follicles re-enter the growth phase on a new synchronized cycle.
A persistent shed beyond 6 to 12 months is less common and warrants a workup for other contributors: iron status (ferritin), thyroid function (TSH, free T4), vitamin D, recent weight loss, and any new medications. It is also worth considering whether an underlying androgenetic alopecia has been unmasked by the telogen shed; the diffuse loss can reveal pre-existing patterned thinning that was previously camouflaged.
Why stopping the antidepressant on your own is the wrong move
This is the single most important point on the page. Antidepressants are prescribed for serious conditions, and the consequences of stopping them improperly are far worse than hair shedding.
Relapse risk. Depression and anxiety have high recurrence rates. Stopping an antidepressant that is working, even temporarily, can trigger a relapse that takes weeks or months to resolve once treatment is restarted. The original episode may have taken significant time and effort to bring under control.
Discontinuation syndrome. Several antidepressants, particularly paroxetine and venlafaxine, cause a withdrawal-like syndrome when stopped abruptly: dizziness, "brain zaps," nausea, irritability, insomnia, and flu-like symptoms. The syndrome resolves with re-initiation or with a slower taper, but it can be deeply unpleasant.
Self-harm risk. Untreated depression carries a meaningful risk of self-harm. This risk is the entire reason antidepressants are prescribed in the first place.
The right move when hair shedding is bothersome is to talk with the prescribing clinician about options.
What to discuss with the prescriber
A productive conversation usually covers a few specific options:
Wait and watch. If the medication is working well and the shedding is in the expected window (months 3 to 6), the most reasonable plan is often to continue and let the cycle complete. Reassurance with a planned follow-up is sometimes all that is needed.
Workup for contributors. Ferritin under 40 to 70 ng/mL, vitamin D under 30 ng/mL, low B12, or a borderline thyroid result can each amplify shedding. Treating any of these makes the telogen effluvium milder and shorter regardless of the medication.
Dose reduction. A modest dose decrease may reduce the burden on the hair cycle while preserving therapeutic benefit. Whether this is feasible depends on how the antidepressant is being used.
Switching agents. If the shedding is severe and persistent, the prescriber may consider switching to an antidepressant with a weaker reported hair-loss signal. Cross-tapering between agents is the usual approach, never abrupt discontinuation.
Topical minoxidil for cosmetic mitigation. For patients with persistent shedding or unmasked androgenetic alopecia, topical minoxidil can shorten the visible shed and improve density without interacting with the antidepressant. This is the most common dermatologic add-on in this situation.
When the loss is patterned rather than diffuse
If the shedding has been going on for more than a year, if it is concentrated at the crown or temples, or if it is part of a longer pattern that predates the antidepressant, the most likely diagnosis is androgenetic alopecia rather than medication-induced telogen effluvium. In that case the antidepressant may be incidental and the treatment plan involves evidence-based options such as topical minoxidil, oral finasteride, or both. The women's pattern hair loss page covers the parallel approach for women.
Telling the two apart is best done with an exam and sometimes a few labs. The distinction matters because the management is different.
Considering medical assessment
If you have been on an antidepressant and have noticed more shedding than usual, the most useful next step is a medical assessment that looks at the timing, the pattern, and any contributing factors. A clinician can determine whether what you are seeing fits telogen effluvium, an unmasked androgenetic pattern, or something else, and can coordinate with the prescriber if a medication change ever comes into the conversation. The Curekey assessment is online and free to start, and it covers the relevant history. Visit /your-plan-2 or read about how it works for more.
